Anavex Life Sciences Corp (AVXL)

[falconer66a]

Product advancement.

...how do you treat 3-71, if it is just a more potent form of 2-73. You don't want to make your primary drug redundant. How does Anavex make them travel on separate tracks?

Well, yes, if Anavex 3-71, at its much lower dosages and greater therapeutic successes thoroughly outperforms Anavex 2-73 (blarcamesine), would that be good, or bad, for the company?

There will be no conflict. Should Anavex 3-71 prove to be better (as I’m certain it will), Anavex will simply market it as what it is, a new, even better sigma-1 receptor activator. It’s what every good business does. Create new, even better products, to replace older, less favorable ones.

In say, five years or so, after blarcamesine is the standard of care (SOC) for a number of big diseases, can you imagine the Anavex advertising campaign: “First, changing everything, it was blarcamesine. Now, even better, it’s (new product name)! Ask your doctor about (new product name)!